Randomised, Controlled Study to Assess Safety and Tolerance of Infant Formula With Prebiotics and Postbiotics in Healthy Infants.
NCT ID: NCT04015050
Last Updated: 2021-12-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
279 participants
INTERVENTIONAL
2019-07-10
2021-12-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Test product
Cow's milk based infant formula containing prebiotics and postbiotics
milk based infant formula
Cows milk ased infant formula
Control product
Cow's milk based infant formula without prebiotics and postbiotics
milk based infant formula
Cows milk ased infant formula
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
milk based infant formula
Cows milk ased infant formula
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2\. Infants with age at screening ≤14 days;
3\. Birth weight within 10th to 90th percentile per gestational age and sex, according to Intergrowth Standards;
4\. Head circumference at screening within ±2 SD per age and sex according to WHO Child Growth Standards;
5\. a Randomised groups: Infants who are exclusively formula fed and/or whose mothers have autonomously decided to exclusively formula feed, i.e. not to breastfeed or have ended breastfeeding before screening, and who are intending to exclusively formula feed at least till their infant is 17 weeks of age; OR b Breastfed reference group: Infants who are exclusively breastfed and whose mothers are intending to exclusively breastfeed at least till their infant is 17 weeks of age;
6\. Written informed consent from parent(s) and/or legal guardian(s) aged ≥18 years at screening.
Exclusion Criteria
2\. Infants with current or previous illnesses/conditions and/or known or suspected congenital diseases or malformations which could interfere with the study or its outcome parameters, such as but not limited to: GI malformations, congenital metabolic disorders, severe congenital cardiac disorders, immunodeficiency or major surgery, as per the clinical judgement of the Investigator;
3\. Infants with previous, current or intended participation in any other clinical study involving investigational or marketed products;
4\. Incapability of infants' parents to comply with study protocol as per the judgement of the Investigator;
5\. Infants born from mothers known to have (any) hepatitis or human immunodeficiency virus;
6\. Infants born from mothers with significant medical conditions during pregnancy that might interfere with the study or its outcome parameters or known to affect intra-uterine growth (e.g. placenta previa, pre-eclampsia, eclampsia, Type 1, 2 diabetes) as per clinical judgement of the Investigator;
7\. Infants born from mothers, who did participate in any clinical study involving investigational products during pregnancy, and for infants in Breastfed reference group: mothers who are currently participating or intend to participate in any clinical study involving investigational products during lactation.
0 Days
17 Weeks
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nutricia Research
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Poliklinika Ginekologiczno-Położnicza Sp. z o.o. Sp. k.
Bialystok, , Poland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EBB18FI23464
Identifier Type: -
Identifier Source: org_study_id